Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D T Jayaweera

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Drug Safety|April 1, 1997
Minimising the dosage-limiting toxicities of foscarnet induction therapyD T Jayaweera
Journal of the Royal Society of Health|February 1, 1993
Pediculosis pubis: a surrogate marker for sexually transmitted diseasesA A Opaneye, D T Jayaweera, M Walzman, et al.
International Journal of STD & AIDS|November 1, 2000
Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infectionsT W Cheung, D T Jayaweera, D Pearce, et al.
Medicina|August 26, 1998
[Cytomegalovirus polyradiculomyelopathy in AIDS]D T Jayaweera, L I Cassetti, L Espinoza, et al.
HIV Medicine|September 17, 2004
Effectiveness and tolerability of a once-daily amprenavir/ritonavir-containing highly active antiretroviral therapy regimen in antiretroviral-naïve patients at risk for nonadherence: 48-week results after 24 weeks of directly observed therapyD T Jayaweera, M A Kolber, M Brill, et al.
HIV Medicine|May 27, 2010
Coinfection with hepatitis C virus, oxidative stress and antioxidant status in HIV-positive drug users in MiamiM K Baum, S Sales, D T Jayaweera, et al.
International Journal of STD & AIDS|July 4, 2008
C-reactive protein: a poor marker of cardiovascular disease risk in HIV+ populations with a high prevalence of elevated serum transaminasesM K Baum, C Rafie, S Sales, et al.
Genitourinary Medicine|April 1, 1997
Hepatitis B markers in heterosexual patients attending two genitourinary medicine clinics in the West MidlandsA A el-Dalil, D T Jayaweera, M Walzman, et al.
International Journal of STD & AIDS|November 20, 2003
The safety and efficacy of indinavir and ritonavir (400/400 mg BID) in HIV-1-infected individuals from an inner-city minority population: a pilot studyD T Jayaweera, E Scerpella, M Robinson, et al.
AIDS (London, England)|April 24, 2001
Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDSJ M Jacobson, R Hafner, J Remington, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Drug Safety|April 1, 1997
Minimising the dosage-limiting toxicities of foscarnet induction therapyD T Jayaweera
Journal of the Royal Society of Health|February 1, 1993
Pediculosis pubis: a surrogate marker for sexually transmitted diseasesA A Opaneye, D T Jayaweera, M Walzman, et al.
International Journal of STD & AIDS|November 1, 2000
Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infectionsT W Cheung, D T Jayaweera, D Pearce, et al.
Medicina|August 26, 1998
[Cytomegalovirus polyradiculomyelopathy in AIDS]D T Jayaweera, L I Cassetti, L Espinoza, et al.
HIV Medicine|September 17, 2004
Effectiveness and tolerability of a once-daily amprenavir/ritonavir-containing highly active antiretroviral therapy regimen in antiretroviral-naïve patients at risk for nonadherence: 48-week results after 24 weeks of directly observed therapyD T Jayaweera, M A Kolber, M Brill, et al.
HIV Medicine|May 27, 2010
Coinfection with hepatitis C virus, oxidative stress and antioxidant status in HIV-positive drug users in MiamiM K Baum, S Sales, D T Jayaweera, et al.
International Journal of STD & AIDS|July 4, 2008
C-reactive protein: a poor marker of cardiovascular disease risk in HIV+ populations with a high prevalence of elevated serum transaminasesM K Baum, C Rafie, S Sales, et al.
Genitourinary Medicine|April 1, 1997
Hepatitis B markers in heterosexual patients attending two genitourinary medicine clinics in the West MidlandsA A el-Dalil, D T Jayaweera, M Walzman, et al.
International Journal of STD & AIDS|November 20, 2003
The safety and efficacy of indinavir and ritonavir (400/400 mg BID) in HIV-1-infected individuals from an inner-city minority population: a pilot studyD T Jayaweera, E Scerpella, M Robinson, et al.
AIDS (London, England)|April 24, 2001
Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDSJ M Jacobson, R Hafner, J Remington, et al.
Pageof 2